Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best-performing stocks in the Nordics each week.

The KPHC index continued its positive performance and it does look more and more like a year-end rebound to the Nordic biotech & healthcare stocks, which would be welcomming for a sector down 25% on a 12-month basis.

The past week was full of news (again); Scandion Oncology reported positive phase 2 data, Ascendis Pharma got EU-approval, Saniona selected a compound for further development, Pila Pharma announced a research collaboration, while Curasight, CS Medica, and 2CureX released earnings reports.

10 of the 20 listed Danish biotech companies published news. 9 of the 20 companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 166% increase.

---

Do you want to stay tuned to the developments of impact companies and stocks in the Nordics? Then we have something for you! We have launched a brand new newsletter that dives into impact stocks listed in the Nordics. The newsletter help you to invest more sustainably in the businesses of tomorrow, track the development of multiple sectors including energy production, waste management, and carbon capture, and follow the developments of over 100 large, medium and small cap companies. Read the first edition here.

---

Danish Company news the past week

Ascendis Pharma

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism (Link)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

Release of 2022/2023 Q4 report, for the period July – September 2023 (Link)

Comment on the earnings by Kapital Partner in Danish (Link)

Curasight

Interim Report January – September 2023 (Link)

Comment on the earnings by Kapital Partner in Danish (Link)

Evaxion Biotech

No news the past week

ExpreS2ion

No news the past week

Fluoguide

No news the past week

Genmab

No news the past week

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

Pila Pharma announces preclinical research collaboration (Link)

Saniona

Saniona promotes Kv7 epilepsy compound to candidate selection phase (Link)

Scandion Oncology

Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months (Link)

Interim Report Q3 2023 (Link)

SynAct Pharma

Nomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB (Link)

ViroGates

Resolutions from the Extraordinary General Meeting of ViroGates A/S (Link)

Zealand Pharma

Nasdaq made changes to OMX Copenhagen Benchmark Index (OMXCB), where Zealand Pharma was added

Y-mAbs Therapeutics

No news the past week

2cureX

2CUREX PUBLISHES INTERIM REPORT FOR THE THIRD QUARTER OF 2023 (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a positive share price performance last week of 3.6% heavily driven by Scandion Oncology. Scandion Oncology became the best-performer after they reported final data from their phase 2 study. Pila Pharma also did well following a collaboration deal with a research group at Uppsala University. Saniona rose 9% after they promoted Kv7, a epilepsy compound, to candidate selection phase. Noteably, Ascendis Pharma fell after they got approval of Yorvipath (TransCon PTH) in Europe. The best stocks year-to-date include Curasight, Cessatech, Fluoguide, and Saniona with performances of 76-166%. Overall, the Danish biotech and healthcare stocks are in negative territory this year with a year-to-date return of -1.7%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date and last twelve months

Nordic biotech and healthcare developments (KPHC-index)

In the past week, the Kapital Partner Nordic Healthcare Index (KPHC) rose 1.2% to 61.80 and thus continues to improve. Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics. It includes large-cap companies such as Novo Nordisk and Genmab as well as smaller companies such as Curasight. In the past 12 months, it has significantly underperformed relative to the C25-index in Copenhagen and S30-index in Stockholm, while the Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

38-54% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Scandion Oncology A/S (54%) (Nordnet) is building a pipeline of drugs that can reverse cancer drug resistance through various mechanisms. The company’s lead candidate SCO-101 for colorectal cancer is in phase 2, while the company also has a phase 1 project with the same agent for pancreatic cancer. Scandion Oncology just reported positive results from their phase 2 their study. Read more here.

Audientes A/S (41%) (Nordnet) is a Danish technology company specializing in the development of hearing aids. Audientes’ hearing aid solution, Ven™ by Audientes, is available in the Indian market, online and through retailers. Audientes’ vision is to develop products that can be used by people suffering from hearing loss who currently do not have access to a solution for their hearing loss.

Hemcheck Sweden AB (38%) (Nordnet) develops and commercializes products for the detection of hemolysis in blood samples. The company has developed products that ensure that the hemolysis is detected at an early stage, which means that the blood sample can be taken care of immediately. The company also develops digital reading that is used as a complement to the main product.

Sources: Refinitiv & Nordnet